Seeking Alpha

Galena Biopharma -6.4% as Jim Cramer says take profits

  • Galena Biopharma (GALE -6.4%) opens with a thud after Jim Cramer suggests investors take profits after shares more than tripled during the past three months.
  • Cramer questioned CEO Dr. Mark Ahn about the history of failures for drugs similar to NeuVax, GALE's lead clinical candidate, saying he was skeptical about the drug's chances for approval.
  • In response to criticisms, Ahn says "of the patients in the Phase II study of NeuVax, 0% of those patients had a recurrence of cancer."
From other sites
Comments (38)
  • DotCom55
    , contributor
    Comments (5) | Send Message
     
    Just a bump on the road, GALE will recover very fast, maybe today
    17 Jan 2014, 09:57 AM Reply Like
  • Cramer disbeliever
    , contributor
    Comment (1) | Send Message
     
    If u ever listen to crame, u will notice that he made more calls wrong than right. Just take what he says with a bucket of salt!
    20 Jan 2014, 03:30 PM Reply Like
  • BrennanNoall
    , contributor
    Comments (72) | Send Message
     
    How does one argue against zero recurrances?
    17 Jan 2014, 10:02 AM Reply Like
  • bk14857
    , contributor
    Comments (28) | Send Message
     
    Cramer is just kissed off because he didn't recognize this small cap and get in at 1.80/share
    17 Jan 2014, 10:06 AM Reply Like
  • BuyToSell
    , contributor
    Comments (236) | Send Message
     
    One thing to be aware of though - once a stock is on Mad Money, its visibility goes way up. Once more people know about it, expect a lot more people trying to trade it, short it, etc. In other words, expect a lot more volatility going forward.
    17 Jan 2014, 10:08 AM Reply Like
  • russleehowe
    , contributor
    Comments (75) | Send Message
     
    Hey Jim, CEO said "Zero recurrances" -- Get it?
    17 Jan 2014, 10:18 AM Reply Like
  • Cala
    , contributor
    Comments (28) | Send Message
     
    Simply put, As an MM, Cramer created a more favorable buying opportunity. Got in @ $7
    17 Jan 2014, 10:30 AM Reply Like
  • arbernstein47
    , contributor
    Comments (7) | Send Message
     
    Go ahead. Follow Jim Cramer's advice. Pay the capital gains on your profits. Then what? If it goes back up, what are you going to do? Buy it back at a higher price? Wait for it to drop more? How much more? Cramer and his "associate" from "The Street" Adam F. have been wrong about this company all along the way. By the way, we haven't heard much from Adam F. lately.
    17 Jan 2014, 10:32 AM Reply Like
  • jonomatic_2000
    , contributor
    Comments (35) | Send Message
     
    Longing GALE. thanks for the info RS and ProtoCola.
    17 Jan 2014, 10:32 AM Reply Like
  • pat walsh
    , contributor
    Comments (284) | Send Message
     
    Adam F would love to work at GS.the mail room has an opening.
    17 Jan 2014, 10:37 AM Reply Like
  • ilex cramer
    , contributor
    Comments (2) | Send Message
     
    Mr. Cramer did not seem to understand the current trial timing and target patients.
    17 Jan 2014, 10:59 AM Reply Like
  • Bob McGin
    , contributor
    Comment (1) | Send Message
     
    Cramer is a Moron.He demonstrated His lack of knowledge and was intimated by Dr.Ahn
    17 Jan 2014, 11:03 AM Reply Like
  • ZenStudent
    , contributor
    Comments (32) | Send Message
     
    Buying opportunity.... Cramer is just wrong on this one
    17 Jan 2014, 11:28 AM Reply Like
  • Sammyboy12
    , contributor
    Comments (110) | Send Message
     
    Very sad. So obviously an effort to back up his short position. Now I know not to take even the time of day as truth from J.C.(Is there some hidden meaning in his initials? Must take another look at The Omen)!
    17 Jan 2014, 11:34 AM Reply Like
  • WilsonWagwa
    , contributor
    Comments (64) | Send Message
     
    Adumb Fartstain tried early on when Galena was 2$ to bash the company to no avail. Now the other clown on TV tries and got destroyed with Mark Ahns professionalism to the clowns spin on Galena. These guys are worthless and only in for the shorts.
    17 Jan 2014, 11:34 AM Reply Like
  • WilsonWagwa
    , contributor
    Comments (64) | Send Message
     
    Investor in GALE
    17 Jan 2014, 11:36 AM Reply Like
  • deercreekvols
    , contributor
    Comments (6829) | Send Message
     
    Mr. Cramer appeared to be in over his head during the interview. Not surprising. He simply can't know everything about every stock, but I would have thought he would have done some research into GALE.

     

    Long GALE.
    17 Jan 2014, 11:51 AM Reply Like
  • poolguy123
    , contributor
    Comments (181) | Send Message
     
    This time not only is Cramer woefully wrong on his misleading and rubbishing claims that Galena has reached its peak and there is no future for the company. He just didnt do his research,presenting worthless pointers which makes them look like fools in the investment circle,maybe he should try another stock with poor fundamentals and on the verge of collapse, he could bash and intimidate those,not Galena or some strong biotech companies with plenty of hope.
    17 Jan 2014, 12:46 PM Reply Like
  • Hdrdr1999
    , contributor
    Comments (9) | Send Message
     
    Cramer has his opinion, but the performance of the company has, and will continue to prove him wrong on GALE.
    17 Jan 2014, 01:33 PM Reply Like
  • Hdrdr1999
    , contributor
    Comments (9) | Send Message
     
    Cramer notwithstanding, nothing to slow Gale. March earnings with Abstral will only push the price higher....
    17 Jan 2014, 01:46 PM Reply Like
  • japalm
    , contributor
    Comments (5) | Send Message
     
    Thanks for pointing out forthcoming Abstral sales...that's important and seems to be missing in the chatter on this exciting company
    20 Jan 2014, 03:16 AM Reply Like
  • Nataku
    , contributor
    Comments (70) | Send Message
     
    only sad thing will be the increased volatility that we will see now in GALE thanks to the exposure...
    17 Jan 2014, 01:46 PM Reply Like
  • BuyToSell
    , contributor
    Comments (236) | Send Message
     
    Turning out to be surprisingly un-volatile, considering. Nearly flat graph on 15 min or higher scale since about 11:30 am. Institutional support remains constant and strong.
    17 Jan 2014, 03:26 PM Reply Like
  • stockhawk
    , contributor
    Comments (259) | Send Message
     
    Cramer probably didn't do his dd on GALE. Very high institutional holdings, NeuVax 78% reduction in cancer in Phase II trial, 2012 Teva collaboration, combo trial with Roche's Herceptin in 2012, Abstral for cancer pain being marketed as we speak, and cash for 2 years out. I'm only summarizing. It certainly has had a great run, but for a reason. I still like it as do others.
    17 Jan 2014, 01:51 PM Reply Like
  • retiredpharma
    , contributor
    Comments (434) | Send Message
     
    stockhawk link please....to this....NeuVax 78% reduction in cancer in Phase II trial?

     

    Really..where did you see this number?

     

    I see this instead....E75 PHASE II CLINICAL TRIALS COMPLETE

     

    Sept. 10 was a key date for the CVDP: Phase II of a clinical trial on a peptide called E75 concluded after eleven years. E75 was discovered in the mid-1990s, and Peoples has taken it through consecutive stages of development -- pre-clinical, clinical and human trials. Phase II of the trial studied E75 in preventing recurrence of breast cancer in a control group of cancer survivors vs. a vaccinated group. The final Phase II report will be delivered at the San Antonio Breast Cancer Symposium in December.

     

    A Phase III trial began in January and will include between 700 and 1,000 breast cancer patients around the world.

     

    "The Phase II trial data has shown that the rate of breast cancer recurrence in women who received E75 was half the rate observed in the control group," said Peoples. "We look forward to seeing if the Phase III trial will confirm these results."

     

    in another posting on SA....RXI stated that the 24 month landmark analysis for E75 was first presented at the ASCO Breast Cancer Meeting in October 2010. The 24 month landmark analysis was actually a cumulative finding of nonrandomized Phase I/II studies of E75, based upon a subset analysis of subjects. While the studies have enrolled 188 subjects, due to trial design, 72 patients received less than what was determined to be the optimal biologic dose.

     

    A subset analysis of the study results, as researchers cull the data, found a grouping of patients with low HER2/neu expression, IHC 1+ and 2+, that are node positive, and whom received six month cycles of booster shots that benefited most from E75. The booster program was initiated after the ongoing studies revealed waning immunity of the E75 vaccine. The researchers found that amongst this subgroup of patients, the E75 vaccine reduced disease recurrence rate by ~ 50% compared to unvaccinated women.

     

    half=50% not 78%!

     

    also E75 Neuvax is MHC-Class1 "restricted" and AE 37 will hit both Class 1 and 2 I believe...

     

    to hear Mark Ahn say 0% recurrence in the Txd group has me a bit suspicious..that almost sounds statistically Impossible and I would need to know the the post vaccine followup time frame for such a claim....we know the recurrence rate was about 10% in the Txd Neuvax group and about 18% in the control/placebo group so that works out to 43% rate of reduction which is still very good imo and worthy of P-3 trial validation! That trial is underway in 15 countries, 150 Hospitals and 700 patients and is a long ways out to get validation data m?ybe 2016!

     

    GALE will need lots more Capital to bring home the Bacon!

     

    RP
    19 Jan 2014, 01:12 PM Reply Like
  • stockhawk
    , contributor
    Comments (259) | Send Message
     
    RP I got the 78.4% from the November 2, 2013 A John Hodge story Five Reasons to Buy GALE. Definitely appreciate you're expertise on pharma and was mainly summarizing the positives going forward. I admit not knowing it all and am still learning.
    20 Jan 2014, 08:18 AM Reply Like
  • Zankudo
    , contributor
    Comments (232) | Send Message
     
    Cramer is a DH.
    17 Jan 2014, 02:43 PM Reply Like
  • Hoang6
    , contributor
    Comments (326) | Send Message
     
    OK, this kind of argument pops up all the time. You can call Cramer (or A. F. or QTR (dislike)) by name or anything you want, he's not gonna hear it or read it. So, why bother? If you believe in the future of the company, you can only prove he's full of s**t by loading this stock on dips, if all the believers do so, then he'll hear it. Why bother explaining he's wrong or not everyday, every time?

     

    The question isn't if Cramer is right or wrong, the question is if you're true believers, because if you're, there's nothing to complain since you know that you'll be richer, period!

     

    I'll bet it will go up next week, and I'm happy!
    17 Jan 2014, 06:43 PM Reply Like
  • gless3940
    , contributor
    Comments (11) | Send Message
     
    I have made good money on gale and although I do a lot of trading I consider this at this time as a long term spec. However it never hurts to take some profits and not get caught up too much in the hype. One never goes broke by being a little more cautious. I have trimmed my position by about 40 percent. I may be wrong but there has been a substantial move and a little consolidation and sidewise move is to be expected. I would like to add to my position at a little lower price. If it continues to go up right now from here I still have a substantial position. Long gale and excited about its future but being a little cautious
    18 Jan 2014, 09:14 AM Reply Like
  • countdodo
    , contributor
    Comments (5) | Send Message
     
    Cramer is a big loudmouth. I dropped him years ago when listening to his bs cost me a lot of money. Ahn should have known better than to go on his show. Cramer is a big tv show phony.
    18 Jan 2014, 10:26 AM Reply Like
  • phaedrus9
    , contributor
    Comments (3) | Send Message
     
    Do any of you remember a few years ago when Cramer spent a whole week pumping Sears Holding (his top pick) before it collapsed ? (Seldom right but never in doubt). He's entertaining, but you're a sheep or a lemming if you are looking to him to lead you to glory.

     

    GALE is currently 10% of my portfolio and I'm pretty far into margin. Since its margin maintenance requirement is 100%, think how much other opportunuty that is costing me. You could definitely say I'm a strong believer in it. It could continue to suffer some emotional weakness in the near term, but longer term its fundementals seem very encouraging. Hang tight, at least for now.
    18 Jan 2014, 10:28 AM Reply Like
  • Nick_C
    , contributor
    Comments (23) | Send Message
     
    Cramer is apparently not a small bio pharma bull, as is reflected in most street.com coverage. He is consistent in steering his viewers away from speculative plays (in my opinion). But his audience, many of whom are needing to catch up from repeated market failures, corporate fraud and general difficulty of aggressive investing in today's markets are apparently asking him to weigh in after seeing GALE run up as it has. Maybe he should do a show on these types of plays, elaborating that the DD required is a bit more than tuning into his show prior to trading, and give some guidelines for his viewers. More education, less spin, and please hire someone with scientific background at the street so the biased analysis has some basis. Long GALE.
    19 Jan 2014, 03:24 AM Reply Like
  • cicciogagiotto
    , contributor
    Comments (17) | Send Message
     
    The only warning could be a placement to finance the trials but i think it could be a buying opp
    19 Jan 2014, 10:35 AM Reply Like
  • russleehowe
    , contributor
    Comments (75) | Send Message
     
    One good thing about Cramer is that he offers a good buying opportunity after he trashes a stock. He killed me in October with his "sell all biotechs" crap. Since taking that -35% hit then I have increased 40% a month from November through mid-January. So much for his advice. He always seems to show up when things are going good. Love GALE too. Up 250% since September.
    19 Jan 2014, 12:58 PM Reply Like
  • tmdoyle_1954
    , contributor
    Comments (3) | Send Message
     
    I don't think Cramer bashed the stock; he merely expressed some reasonable concerns. Nothing personal; nothing personal AT ALL.

     

    As has been noted above, he probably did all of us who have been here for more than a year or so a GREAT service. He got our CEO on a major TV network; the name GALE is now mentioned in the same company of legitimate biotecs.

     

    Anyone who has done their proper DD knows the science is there; not everyone in Florence sang Galileo's discoveries when he circulated them.

     

    Methinks the biggest challenge (at least for me) is to decide how much of my overall portfolio is dedicated to GALE. In a world of 280 stocks (I reference IBD's industry groups), there are MANY other worthy companies out there.

     

    I am now off my soapbox.
    19 Jan 2014, 08:42 PM Reply Like
  • BuyToSell
    , contributor
    Comments (236) | Send Message
     
    Great and illuminating presentation by GALE CEO on their science live now at Noble TEN conference - hopefully will be reposted, since it started 20 mins ago

     

    where they will post the presentation later if you missed it http://bit.ly/1f5DxY9
    20 Jan 2014, 10:50 AM Reply Like
  • stinky333
    , contributor
    Comments (6) | Send Message
     
    Gale is on the right track just have to have successful phase 3 70 percent of drugs fail in phase 3 trials if they complete it without any setbacks great but say what you want that neuvax is a gold mine but the final word comes from the FDA . Case in point aveo gold mine drug but FDA shot it down
    21 Jan 2014, 09:02 AM Reply Like
  • billeebong
    , contributor
    Comments (178) | Send Message
     
    ...GALE is on my watch list but after reading this and seeing how easily Cramer can manipulate a stock...9 Jan, "late stage oncology company that I'm willing to bless, said Cramer. Something big could happen here." where the stock hovered around $6 and then went right up to $7.50 a day later. Then he does a segment on 17 Jan on GALE, and says ""Personally, if you're long, after Galena's incredible run I think you'd be nuts not to ring the register," and GALE spikes down to $5.90, I think I will subscribe to his private line to get in on these convulsions real time...:) Just goes to show you that you can talk fundamentals all day long, but if someone like Cramer speaks you'd better already be on the right side of the spike...Wow...
    21 Jan 2014, 11:36 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs